These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

244 related articles for article (PubMed ID: 30050352)

  • 21. Elimination of lymphatic filariasis in west African urban areas: is implementation of mass drug administration necessary?
    Koudou BG; de Souza DK; Biritwum NK; Bougma R; Aboulaye M; Elhassan E; Bush S; Molyneux DH
    Lancet Infect Dis; 2018 Jun; 18(6):e214-e220. PubMed ID: 29402636
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Increasing evidence of low lymphatic filariasis prevalence in high risk Loa loa areas in Central and West Africa: a literature review.
    Kelly-Hope LA; Hemingway J; Taylor MJ; Molyneux DH
    Parasit Vectors; 2018 Jun; 11(1):349. PubMed ID: 29907117
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment strategies underpinning the global programme to eliminate lymphatic filariasis.
    Gyapong JO; Kumaraswami V; Biswas G; Ottesen EA
    Expert Opin Pharmacother; 2005 Feb; 6(2):179-200. PubMed ID: 15757416
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The safety of double- and triple-drug community mass drug administration for lymphatic filariasis: A multicenter, open-label, cluster-randomized study.
    Weil GJ; Bogus J; Christian M; Dubray C; Djuardi Y; Fischer PU; Goss CW; Hardy M; Jambulingam P; King CL; Kuttiat VS; Krishnamoorthy K; Laman M; Lemoine JF; O'Brian KK; Robinson LJ; Samuela J; Schechtman KB; Sircar A; Srividya A; Steer AC; Supali T; Subramanian S;
    PLoS Med; 2019 Jun; 16(6):e1002839. PubMed ID: 31233507
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Mass drug administration of ivermectin, diethylcarbamazine, plus albendazole compared with diethylcarbamazine plus albendazole for reduction of lymphatic filariasis endemicity in Papua New Guinea: a cluster-randomised trial.
    Laman M; Tavul L; Karl S; Kotty B; Kerry Z; Kumai S; Samuel A; Lorry L; Timinao L; Howard SC; Makita L; John L; Bieb S; Wangi J; Albert JM; Payne M; Weil GJ; Tisch DJ; Bjerum CM; Robinson LJ; King CL
    Lancet Infect Dis; 2022 Aug; 22(8):1200-1209. PubMed ID: 35533701
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The role of medicine donations in the global programme for the elimination of lymphatic filariasis.
    Williams T; Taylor R; Iwamoto M; Hida T; Gusovsky F
    Int Health; 2020 Dec; 13(Suppl 1):S39-S43. PubMed ID: 33349878
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The impact of six rounds of single-dose mass administration of diethylcarbamazine or ivermectin on the transmission of Wuchereria bancrofti by Culex quinquefasciatus and its implications for lymphatic filariasis elimination programmes.
    Ramaiah KD; Das PK; Vanamail P; Pani SP
    Trop Med Int Health; 2003 Dec; 8(12):1082-92. PubMed ID: 14641843
    [TBL] [Abstract][Full Text] [Related]  

  • 28. First evidence of lymphatic filariasis transmission interruption in Cameroon: Progress towards elimination.
    Nana-Djeunga HC; Tchouakui M; Njitchouang GR; Tchatchueng-Mbougua JB; Nwane P; Domche A; Bopda J; Mbickmen-Tchana S; Akame J; Tarini A; Epée E; Biholong BD; Zhang Y; Tougoue JJ; Kabore A; Njiokou F; Kamgno J
    PLoS Negl Trop Dis; 2017 Jun; 11(6):e0005633. PubMed ID: 28662054
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Albendazole alone or in combination with microfilaricidal drugs for lymphatic filariasis.
    Macfarlane CL; Budhathoki SS; Johnson S; Richardson M; Garner P
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD003753. PubMed ID: 30620051
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Identifying co-endemic areas for major filarial infections in sub-Saharan Africa: seeking synergies and preventing severe adverse events during mass drug administration campaigns.
    Cano J; Basáñez MG; O'Hanlon SJ; Tekle AH; Wanji S; Zouré HG; Rebollo MP; Pullan RL
    Parasit Vectors; 2018 Jan; 11(1):70. PubMed ID: 29382363
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Role of vector control in the global program to eliminate lymphatic filariasis.
    Bockarie MJ; Pedersen EM; White GB; Michael E
    Annu Rev Entomol; 2009; 54():469-87. PubMed ID: 18798707
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Assessment of lymphatic filariasis prior to re-starting mass drug administration campaigns in coastal Kenya.
    Njenga SM; Kanyi HM; Mutungi FM; Okoyo C; Matendechero HS; Pullan RL; Halliday KE; Brooker SJ; Wamae CN; Onsongo JK; Won KY
    Parasit Vectors; 2017 Feb; 10(1):99. PubMed ID: 28228160
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Information technology in morbidity management of human lymphatic filariasis-A promising tool in global programme for elimination of lymphatic filariasis.
    Devi RR; Raju V
    J Vector Borne Dis; 2018; 55(1):20-25. PubMed ID: 29916444
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Elimination of lymphatic filariasis as a public health problem from the Arab Republic of Egypt.
    Ramzy RMR; Kamal HA; Hassan MA; Haggag AA
    Acta Trop; 2019 Nov; 199():105121. PubMed ID: 31400299
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can malaria vector control accelerate the interruption of lymphatic filariasis transmission in Africa; capturing a window of opportunity?
    Kelly-Hope LA; Molyneux DH; Bockarie MJ
    Parasit Vectors; 2013 Feb; 6():39. PubMed ID: 23433078
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A refined and updated health impact assessment of the Global Programme to Eliminate Lymphatic Filariasis (2000-2020).
    Turner HC; Ottesen EA; Bradley MH
    Parasit Vectors; 2022 May; 15(1):181. PubMed ID: 35643508
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The story of Lymphatic Filariasis elimination as a public health problem from Yemen.
    Al-Kubati AS; Al-Samie AR; Al-Kubati S; Ramzy RMR
    Acta Trop; 2020 Dec; 212():105676. PubMed ID: 32828916
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An open label, block randomized, community study of the safety and efficacy of co-administered ivermectin, diethylcarbamazine plus albendazole vs. diethylcarbamazine plus albendazole for lymphatic filariasis in India.
    Jambulingam P; Kuttiatt VS; Krishnamoorthy K; Subramanian S; Srividya A; Raju HKK; Rahi M; Somani RK; Suryaprakash MK; Dwivedi GP; Weil GJ
    PLoS Negl Trop Dis; 2021 Feb; 15(2):e0009069. PubMed ID: 33591979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Keeping communities at the centre of efforts to eliminate lymphatic filariasis: learning from the past to reach a future free of lymphatic filariasis.
    Krentel A; Gyapong M; McFarland DA; Ogundahunsi O; Titaley CR; Addiss DG
    Int Health; 2020 Dec; 13(Supplement_1):S55-S59. PubMed ID: 33349882
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Mathematical modelling of lymphatic filariasis elimination programmes in India: required duration of mass drug administration and post-treatment level of infection indicators.
    Jambulingam P; Subramanian S; de Vlas SJ; Vinubala C; Stolk WA
    Parasit Vectors; 2016 Sep; 9(1):501. PubMed ID: 27624157
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.